Vertigo3d
Cingulate (NASDAQ:CING) said it has completed a Phase 3 study for its drug candidate CTx-1301 in the treatment of ADHD in adults and has slated the initiation of a pivotal Phase 3 pediatric study to begin in Q3.
Cingulate expects to receive results from the Phase 3 trial for adults in Q3. If results from the Phase 3 studies are positive, the company hopes to file for US regulatory approval for the drug in mid-2004.
CTx-1301, also known as dexmethylphenidate, is a once-daily treatment for attention deficit/hyperactivity disorder, or ADHD. Cingulate said it believes the drug addresses an unmet need in the ADHD market by offering improved onset and duration.
More on Cingulate:
Cingulate Inc. SEC Filing – Quarterly Report (10-Q) May 10, 2023
Cingulate files with SEC for stock, warrants offering; inks commercialization pact for ADHD drug
Cingulate pops ~76% after hours on trial results for its ADHD treatment drug
Image and article originally from seekingalpha.com. Read the original article here.